Recursion Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was the recipient of unusually large options trading on Wednesday. Investors bought 69,699 call options on the stock. This is an increase of approximately 172% compared to the average volume of 25,642 call options.

Analyst Ratings Changes

RXRX has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Wednesday. Morgan Stanley began coverage on Recursion Pharmaceuticals in a report on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $7.25.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX opened at $6.09 on Thursday. The stock has a market capitalization of $2.64 billion, a P/E ratio of -3.42 and a beta of 0.91. Recursion Pharmaceuticals has a 1 year low of $3.79 and a 1 year high of $12.36. The business’s fifty day moving average is $5.08 and its two-hundred day moving average is $5.13. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.58 and a current ratio of 3.58.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The firm had revenue of $19.10 million for the quarter, compared to analysts’ expectations of $15.38 million. During the same quarter in the previous year, the firm posted ($0.40) earnings per share. The company’s revenue for the quarter was up 33.3% on a year-over-year basis. On average, research analysts forecast that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Najat Khan sold 36,599 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $5.52, for a total transaction of $202,026.48. Following the sale, the insider owned 668,197 shares of the company’s stock, valued at $3,688,447.44. The trade was a 5.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 8.43% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. TD Waterhouse Canada Inc. grew its position in Recursion Pharmaceuticals by 64.1% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock worth $29,000 after purchasing an additional 2,200 shares in the last quarter. AlphaQuest LLC purchased a new position in Recursion Pharmaceuticals during the 1st quarter worth approximately $36,000. GAMMA Investing LLC grew its position in Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after purchasing an additional 2,026 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its position in Recursion Pharmaceuticals by 97.2% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company’s stock worth $46,000 after purchasing an additional 4,446 shares in the last quarter. Finally, Janney Montgomery Scott LLC purchased a new position in Recursion Pharmaceuticals during the 2nd quarter worth approximately $51,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.